Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CPRX 
Catalyst Pharmaceuticals Inc (CPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.29
1 Year Target Price $34.29
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.87% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.49B USD | Price to earnings Ratio 12.35 | 1Y Target Price 34.29 |
Price to earnings Ratio 12.35 | 1Y Target Price 34.29 | ||
Volume (30-day avg) 7 | Beta 0.7 | 52 Weeks Range 19.00 - 26.58 | Updated Date 08/28/2025 |
52 Weeks Range 19.00 - 26.58 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.39 | Actual 0.68 |
Profitability
Profit Margin 37.36% | Operating Margin (TTM) 45.24% |
Management Effectiveness
Return on Assets (TTM) 18.13% | Return on Equity (TTM) 28.49% |
Valuation
Trailing PE 12.35 | Forward PE 10.35 | Enterprise Value 1821265491 | Price to Sales(TTM) 4.47 |
Enterprise Value 1821265491 | Price to Sales(TTM) 4.47 | ||
Enterprise Value to Revenue 3.26 | Enterprise Value to EBITDA 6.48 | Shares Outstanding 122391000 | Shares Floating 115016952 |
Shares Outstanding 122391000 | Shares Floating 115016952 | ||
Percent Insiders 6.2 | Percent Institutions 85.5 |
Upturn AI SWOT
Catalyst Pharmaceuticals Inc
Company Overview
History and Background
Catalyst Pharmaceuticals, Inc. was founded in 2002. It focuses on developing and commercializing therapies for rare neurological diseases. Key milestones include FDA approval of Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS) and the subsequent commercialization of the product.
Core Business Areas
- Neurology: Develops and commercializes therapies for rare neurological diseases, primarily focusing on Lambert-Eaton Myasthenic Syndrome (LEMS).
- Orphan Drugs: Focuses on drugs that treat rare diseases, addressing unmet medical needs.
Leadership and Structure
Patrick J. McEnany is the Chairman and CEO. The company has a typical corporate structure with departments for research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Firdapse: Firdapse (amifampridine) is a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst has significant market share for LEMS treatment, with revenue primarily derived from Firdapse sales. Competitors include Jacobus Pharmaceutical (Ruzurgi) (although market access disputes exist).
Market Dynamics
Industry Overview
The orphan drug market is growing due to increased awareness of rare diseases and regulatory incentives for drug development. It is competitive with many players.
Positioning
Catalyst is a key player in the LEMS treatment market, focusing on commercializing Firdapse. Their competitive advantage lies in their established presence and distribution network.
Total Addressable Market (TAM)
The TAM for LEMS treatment is estimated to be several hundred million dollars annually. Catalyst is well-positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Established product in Firdapse
- Focus on rare neurological diseases
- Strong commercialization capabilities
Weaknesses
- Reliance on a single product
- Litigation risks
- Pricing controversies
Opportunities
- Expansion into new indications
- Acquisitions of complementary assets
- Geographic expansion
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
Competitors and Market Share
Key Competitors
- JAZZ
- AMRX
Competitive Landscape
Catalyst has a strong position in the LEMS market, but faces competition from larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the commercial success of Firdapse.
Future Projections: Future growth will likely depend on expanding Firdapse's indications and potential acquisitions.
Recent Initiatives: Recent initiatives may include pursuing additional indications for Firdapse and exploring potential acquisitions.
Summary
Catalyst Pharmaceuticals is a focused player in the rare neurological disease market, primarily relying on Firdapse for revenue. The company has shown strong growth due to Firdapse's success but faces risks associated with single-product dependence and pricing pressures. Future growth depends on expanding indications, strategic acquisitions, and managing competitive threats. Overall, the company has a solid market position but must diversify to ensure long-term sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catalyst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Coral Gables, FL, United States | ||
IPO Launch date 2006-11-08 | President, CEO & Director Mr. Richard John Daly M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://catalystpharma.com |
Full time employees 181 | Website https://catalystpharma.com | ||
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.